Royalty re-purchase dents Glenmark's 2Q profit but launches help revenues surge 46%
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has reported a 35% decline in net profit to Rs558.5 million ($11.3 million) for the second quarter ended September 2011, as against Rs861.7 million in the corresponding period a year ago, dented by a one-time exceptional expense and mark-to-market losses from foreign currency loans.